Back to Find a Doctor
Frederic F. Rahbari Oskoui

Frederic F. Rahbari Oskoui, MD MS FASN

Dr. Rahbari Oskoui graduated from Medical School In France (University of Bordeaux), where he also completed a residency program and partial nephrology training. He moved to the US in 1999 and redid his Internal medicine residency program at St. Vincemt’s Medical Center-Columbia Univeristy College of Physicians and Surgeons and his Nephrology fellowship at Emory Univeristy, where he joined the faculty in 2006.
Dr. Rahbari has been an active teacher, clinician and a clinical investigator with a particular interest in renal cystic diseases, hypertension and renal imaging. He has been involved in the landmark SPRINT, HALT-PKD and TEMPO trials amongst many other projects. His teaching and clinical skills have been recognized many times at Emory University School of Medicine.

Specialties

  • Nephrology
  • Internal Medicine

Board Certifications

  • ABMS Internal Medicine

Fellowships

  • Emory University School of Medicine

Affiliations

  • Emory

Education & Training

  • Medical School: University of Bordeaux-II
  • Residency: St. Vincent's Medical Center

Honors & Awards

Emory "Teach 12 award" of the Academy of Medical Educators- 2017

Emory Healthcare Featured Faculty of the year

Emory Nephrology “Faculty of the year 2010-2011 award” (for commitment to fellows education)

Fellow of the American Society of Nephrology

Publications

“Effect of age on the Breath Methylated Alkane Contour: An apparent new marker of Oxidative Stress” M. Phillips, R.Cataneo, J. Greenberg, R. Gunawardena, Naidu A, F. Rahbari-0skoui J Lab Clin Med. 2000 Sep; 136(3):243-249.

Volatile Markers of Breast Cancer in the Breath. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C Breast J. 2003 May; 9(3):184-191.

Increased oxidative stress in younger as well as in older humans. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Rahbari-Oskoui F Clin Chim Acta. 2003 Feb; 328(1-2):83-86.

Predictors of blood pressure response to the Angiotensin receptor blocker candesartan in essential hypertension. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Am J Hypertens. 2008 Jan;21(1):61-66.

Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Rizk D, Jurkovitz C, Veledar E, Bagby S, Baumgarten DA, Rahbari-Oskoui F, Steinman T, Chapman AB. Clin J Am Soc Nephrol. 2009 Mar;4(3):560-566. Epub 2009 Mar 4.

The halt polycystic kidney disease trials: design and implementation. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari-Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW. Clin J Am Soc Nephrol. 2010 Jan;5(1):102-109.

Short term Reproducibility of Ambulatory Blood pressure monitoring in Autosomal dominant Polycystic Kidney disease Rahbari-Oskoui F, Miskulin D, Fielder O, Hogan M, Torres VE, Chapman AB, Blood Press Monit. 2011 Apr;16(2):47-54.

Cardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui FF, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Bae KT; for the HALT PKD Study Group. Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-2515. Epub 2011 Sep 8.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPO Formula and 156-05-002 Study Investigators. Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-2507. Epub 2011 Sep 8. Note: Due to the large number of Tempo investigators, the complete list of co-authors is only available as an appendix. the list can be reviewed on the pubmed citation.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Rahbari Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW. Kidney Int. 2012 Mar;81(6):577-585. Epub 2011 Dec 28.

Renal ultrasonography for nephrologists: unmet expectations Frederic Rahbari-Oskoui and William Charles O’Neill ASN kidney news, Feb 2012 12) Tolvaptan in patients with autosomal dominant polycystic kidney disease. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. N Engl J Med. 2012 Dec 20;367(25):2407-2418. Note: Due to the large number of Tempo investigators, the complete list of co-authors is only available as an appendix. the list can be reviewed on the pubmed citation.

Prolonged Recovery Time from Zoledronic Acid Induced Acute Tubular Necrosis: A Case Report and Review of the Literature Rahbari-Oskoui F, Fielder O, Ghasemzadeh N, Hennigar. Case Rep Nephrol. 2013; 2013:651246. doi: 10.1155/2013/651246. Epub 2013 Jul 29.

Letter to the Editor: Impact of MALDI-TOF will be highly dependent of the clinician. Béraud G, Garcia M, Rahbari-Oskoui FF. Clin Infect Dis. 2013 Aug 9.

Variable Clinical Presentation of MUC1 Mutations Causing Medullary Cystic Kidney Disease Type 1 Bleyer AJ, Antignac C, Kmoch S, Robins V, Kidd K, Kelsoe JR, Hladik G, Klemmer P, Knohl S, Scheinman S, Kimmel P, Vo N, Santi A, Harris A, Canaday O, Weller N, Hulick P, Vogel K, Rahbari-Oskoui FF, Tuazon J, Deltas C, Somers D, Rafey M, Bleyer AJ, Hodaňová K, Vyleťal P, Živná M, Hart PS. Clin J Am Soc Nephrol. 2014 Mar;9(3):527-35. doi: 10.2215/CJN.06380613. Epub 2014 Feb 7.

Health Related Quality of Life in Patients with Autosomal Dominant Polycystic Kidney Disease and Stages I-IV Chronic Kidney Disease: A Cross Sectional Study". Miskulin DV, Abebe KZ, Chapman AB, Perrone R, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer F, Hogan M, Rahbari-Oskoui F, Moore C, Flessner M, Schrier RW. Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.

Liver involvement in early autosomal dominant polycystic kidney disease; analysis of 558 patients in the HALT-PKD cohort. Hogan MC, Abebe KZ, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Brian W, Winklhofer FT, Miskulin DC, Rahbari-oskoui F, T. Winklhofer, Masoumi A, Spillane S, Morre CG, Flessner M, Schrier RW. Clin Gastroenterol Hepatol. 2014 Aug 9. pii: S1542-3565(14)01135-5.

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, RahbariOskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; the HALT-PKD Trial Investigators. N Engl J Med. 2014 Dec 11;371(24):22552266. Epub 2014 Nov 15.

Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, RahbariOskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; the HALT-PKD Trial Investigators. N Engl J Med. 2014 Dec 11;371(24):2267-2276. Epub 2014 Nov 15

A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, Mrug M, Bae KT, Wu Z, Ge Y, Landslittel D, Gibbs P, O'Neill WC, Chapman AB. Kidney Int. 2015 Apr 1. doi: 10.1038/ki.2015.71

Closeout of the HALT-PKD trials. Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC. Contemp Clin Trials. 2015 Jul 29;44:48-55. doi: 10.1016/j.cct.2015.07.017.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group, N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.

Dietary Salt restriction is beneficial to management of autosomal dominant polycystic kidney disease. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Moore CG, Flessner MF. Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE, The Halt Pkd Investigators. Curr Hypertens Rev. 2017 Apr 27.

Acquired cystic disease of the kidney in adults Chapman AB, Rahbari-Oskoui F and Bennett W In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2006-Present

Course and treatment of autosomal dominant polycystic kidney disease Chapman AB, Rahbari-oskoui F and Bennett W In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2006-Present

Hypertension in polycystic kidney disease Chapman AB, Rahbari-oskoui F and Bennett W In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2006-Present

Renal manifestations of polycystic kidney disease Chapman AB, Rahbari-oskoui F and Bennett W In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2006-Present

Urinary tract infection in polycystic kidney disease Chapman AB, Rahbari-oskoui F and Bennett W: In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2006- Present

Patient information: Polycystic kidney disease. Chapman AB, Rahbari-oskoui F and Bennett W In UpToDate, edited by Burton D Rose, and published by UpToDate in Wellesley, MA. 2011-Present

Hypertension in autosomal dominant polycystic kidney disease. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Adv Chronic Kidney Dis. 2010 Mar;17(2):153-63.

Hypertension in Autosomal Dominant Polycystic Kidney Disease Arlene Chapman, Frederic Rahbari-Oskoui , Stinne Errboe, Dana Rizk, US Nephrology June 2010

Angiotensin receptor Blockers and risk of cancer; Cause for concern? Frederic Rahbari-Oskoui Am J Kidney Dis. 2011 Jan; 57(1):7-10. Epub 2010 Nov 30. PMID: 21122962

Hypertension in Autosomal Dominant Polycystic kidney disease Frederic Rahbari-Oskoui and Arlene Chapman E-book publication May 2012

Renal relevant radiology: Radiologic imaging in Autosomal Dominant Polycystic Kidney Disease Rahbari-Oskoui FF, Mittal A, Mittal P, Chapman AB Clin J Am Soc Nephrol. 2014 Feb;9(2):406-15. doi: 10.2215/CJN.08940813. Epub 2013 Dec 26.

Mecahnism and management of Hypertension in Autosomal Dominant Polycystic Kidney Disease Rahbari-Oskoui FF, Williams O, Chapman AB Nephrol Dial Transplant. 2014 Dec;29(12):2194-201

Renal Cystic Kidney diseases Board Review material of the American Socitey of nephrology “Nephsaps” Chapters on ADPKD, Medullary Cystic Kidney Disease, Juvenile nephronopthisis Sep 2015 14- Diagnosis and management of acquired cystic kidney disease and renal tumors in ESRD population. Rahbari-Oskoui FF, O’Neill WC Semin Dial. 2017 Jul;30(4):373-379. doi: 10.1111/sdi.12605. Epub 2017 May 21